News

ABSTRACT  Cluster of differentiation 38 (CD38) is an ecto-enzyme expressed primarily on immune cells that metabolize nicotinamide adenine dinucleotide (NAD+) to adenosine diphosphate ribose or cyclic ADP-ribose and nicotinamide. Other substrates of CD38 include nicotinamide adenine dinucleotide phosphate and nicotinamide mononucleotide, a critical NAD+ precursor in the salvage pathway. NAD+ is an important coenzyme

Investment in the startup has led to a series of profitable deals, including one with AstraZeneca worthnearly $1.27 billion. Venture-capital backers of Teneobio Inc. have parlayed their bet on the biotechnology startup into a series of acquisition deals, illustrating the creativity some investors are using to wring profits from the sector.  Typically, venture capitalists

Original Article By Galym Imanbayev and Jonathan MacQuitty - on Medium Today, AstraZeneca announced its agreement to acquire TeneoTwo, a subsidiary of TBio which is managed by Ancora Biotech, for $100M upfront as part of a total transaction value of $1.265B including milestones. The acquisition will accelerate the development of TeneoTwo’s CD19/CD3 T-cell engager for

TNB-486 will be evaluated in multiple types of lymphoma AstraZeneca today announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma1. The acquisition of TNB-486 aims to accelerate the development of this potential new medicine for B-cell haematologic

By Kyle LaHucik, Endpoints The father-son duo behind Teneobio is back with another biotech, comprising three bispecific antibodies that neither Amgen wanted when dishing out $900 million upfront last year, nor AbbVie wanted when acquiring a multiple myeloma asset in 2019. Technically, Ancora Biotech is three shell companies, one for each of its antibodies

A new $126 million series A round will recapitalize Singapore-based Tessa Therapeutics Ltd. as it advances a pipeline ofcell therapies, including one headed into a pivotal study.Polaris Partners led the round alongside prior investorsTemasek, EDBI, Heliconia Capital and Heritas Capital. Thebiotech had raised at least $130 million during 2017-18, buthas shifted focus to its current

Newly-Formed Ancora Biotech Will Continue Operations of Teneobio Spin-offs After Successful Acquisition of Teneobio by Amgen NEWARK, Calif., October 26, 2021 - Ancora Biotech announced, in connection with the closing of the acquisition of Teneobio, Inc., by Amgen Inc., that Teneobio’s former shareholders and their representatives will provide oversight of three previous affiliates of